RESUMO
BACKGROUND: Breath-holding spells are a benign condition primarily seen in 3% to 5% of healthy children aged between six months and five years. Although no specific treatment is recommended due to its benign nature, iron and piracetam are used in severe or recurrent cases. We planned to compare the heart rate variability (HRV) before and after treatment with 24-hour Holter monitoring in patients receiving iron and piracetam treatment and investigate the treatment's effectiveness. METHODS: Twenty-five patients who applied to the outpatient clinic between 2013 and 2015 due to breath-holding spells were included in the study. The patients who received piracetam and iron therapy and underwent 24-hour rhythm Holter monitoring were evaluated retrospectively. RESULTS: Fourteen (56%) of these patients were evaluated as having cyanotic-type and 11 (44%) patients were assessed as having pale-type breath-holding spells. A significant difference was found only between hourly peak heart rate and total power in the group receiving iron treatment. Significant differences were also found among the minimum heart rate, mean heart rate, the standard deviation of RR intervals, the mean square root of the sum of the squares of their difference between adjacent RR intervals, spectpow, and low frequency before and after the treatment in the patients who started piracetam treatment (P < 0.05). CONCLUSIONS: Our study is critical as it is the first to investigate the effects of treatment options on various HRV in patients with breath-holding spells. There were statistically significant changes in HRV parameters in patients receiving piracetam, and the number of attacks decreased significantly. Piracetam treatment contributes positively to the breath-holding spell with regard to efficacy and HRV, therefore it can be used to treat breath-holding spells.
Assuntos
Suspensão da Respiração , Frequência Cardíaca , Piracetam , Humanos , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Suspensão da Respiração/efeitos dos fármacos , Masculino , Feminino , Pré-Escolar , Estudos Retrospectivos , Lactente , Piracetam/farmacologia , Piracetam/administração & dosagem , Piracetam/uso terapêutico , Eletrocardiografia Ambulatorial/efeitos dos fármacos , Resultado do Tratamento , Ferro/administração & dosagem , Ferro/farmacologiaRESUMO
R-phenylpiracetam (R-PhP, (4R)-2-(4-phenyl-2-oxopyrrolidin-1-yl)acetamide) is an optical isomer of phenotropil, a clinically-used nootropic drug that improves physical condition and cognition. Recently, R-PhP was shown to bind to the dopamine transporter (DAT). Since growing evidence suggests that dysfunction of the dopaminergic system is associated with persistent neuroinflammation, the aim of this study was to determine whether R-PhP, an inhibitor of DAT, has neuroprotective and anti-inflammatory effects in male mice. The pharmacokinetic profiles of R-PhP in mouse plasma and its bioavailability in brain tissue were assessed. To study possible molecular mechanisms involved in the anti-inflammatory activity of R-PhP, target profiling was performed using radioligand binding and enzymatic activity assays. To clarify the neuroprotective and anti-inflammatory effects of R-PhP, we used a lipopolysaccharide (LPS)-induced endotoxaemia model characterized by reduced body temperature and overexpression of inflammatory genes in the brain. In addition, the antinociceptive and anti-inflammatory effects of R-PhP were tested using carrageenan-induced paw oedema and formalin-induced paw-licking tests. R-PhP (50 mg/kg) reached the brain tissue 15 min after intraperitoneal (ip) and peroral (po) injections. The maximal concentration of R-PhP in the brain tissues was 28 µg/g and 18 µg/g tissue after ip and po administration, respectively. In radioligand binding assays, DAT was the only significant molecular target found for R-PhP. A single ip injection of R-PhP significantly attenuated the LPS-induced body temperature reduction and the overexpression of inflammatory genes, such as tumour necrosis factor-α (TNF-α), interleukin 1 beta (IL-1ß) and inducible nitric oxide synthase (iNOS). Seven-day po pretreatment with R-PhP dose-dependently reduced paw oedema and the antinociceptive response, as shown by the carrageenan-induced paw oedema test. In addition, R-PhP decreased the nociceptive response during the inflammatory phase in the formalin-induced paw-licking test. Our study showed that R-PhP possesses neuroprotective and anti-inflammatory effects, demonstrating the potential of DAT inhibitors as effective therapeutics.
Assuntos
Anti-Inflamatórios/farmacologia , Inflamação/tratamento farmacológico , Fármacos Neuroprotetores/farmacologia , Piracetam/análogos & derivados , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/farmacocinética , Disponibilidade Biológica , Encéfalo/metabolismo , Encéfalo/patologia , Modelos Animais de Doenças , Proteínas da Membrana Plasmática de Transporte de Dopamina/antagonistas & inibidores , Relação Dose-Resposta a Droga , Inflamação/patologia , Masculino , Camundongos , Camundongos Endogâmicos ICR , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/farmacocinética , Piracetam/administração & dosagem , Piracetam/farmacocinética , Piracetam/farmacologia , Estereoisomerismo , Distribuição TecidualRESUMO
Vascular dementia is considered a vascular cognitive impairment disease caused by neuronal degeneration in the brain. Several studies have supported the hypothesis that oxidative stress and endothelial dysfunction are the main pathogenic factors in vascular dementia. This current study aims to determine the possible neuroprotective effects of zafirlukast, piracetam and the combination of piracetam and zafirlukast on L-methionine-induced vascular dementia in rats. Male Wistar albino rats were divided into five groups. Group I was the normal control, and group II received L-methionine (1700 mg/kg, P.O.) for 32 days. The remaining groups received zafirlukast (20 mg/kg, P.O.), piracetam (600 mg/kg, P.O.) or their combination (zafirlukast 20 mg/kg + piracetam 600 mg/kg, P.O.) for 32 days after L-methionine administration. Afterwards, the cognitive and memory performances of the rats were investigated using the novel object recognition (NOR) test; rats were then sacrificed for histopathological and biochemical analyses. L-methionine-induced vascular dementia altered rats' behaviours and the brain contents of different neurotransmitters and acetylcholinesterase activity while increasing levels of oxidative stress and causing notable histopathological alterations in brain tissues. The treatment of vascular dementia with zafirlukast and the combination improved neurochemical, behavioural and histological alterations to a comparable level to those of piracetam. Thus, zafirlukast, piracetam and the combination of both drugs can be considered as potential therapeutic strategies for the treatment of vascular dementia induced by L-methionine. To the best of our knowledge, this study is the first to explore the neuroprotective effects of zafirlukast and piracetam on L-methionine-induced vascular dementia.
Assuntos
Demência Vascular/tratamento farmacológico , Fármacos Neuroprotetores/farmacologia , Piracetam/farmacologia , Compostos de Tosil/farmacologia , Acetilcolina/análise , Animais , Encéfalo/patologia , Química Encefálica/efeitos dos fármacos , Quimioterapia Combinada , Indóis , Interleucina-6/análise , Masculino , Metionina/farmacologia , Fenilcarbamatos , Piracetam/administração & dosagem , Ratos , Ratos Wistar , Sulfonamidas , Compostos de Tosil/administração & dosagemRESUMO
Unverricht-Lundborg disease (ULD) is a form of progressive myoclonus epilepsy characterized by stimulation-induced myoclonus and seizures. This disease is an autosomal recessive disorder, and the gene CSTB, which encodes cystatin B, a cysteine protease inhibitor, is the only gene known to be associated with ULD. Although the prevalence of ULD is higher in the Baltic region of Europe and the Mediterranean, sporadic cases have occasionally been diagnosed worldwide. The patient described in the current report showed only abnormally enlarged restriction fragments of 62 dodecamer repeats, confirming ULD, that were transmitted from both her father and mother who carried the abnormally enlarged restriction fragment as heterozygotes with normal-sized fragments. We report the first case of a genetically confirmed patient with ULD in Korea.
Assuntos
Cistatina B/genética , Convulsões/fisiopatologia , Síndrome de Unverricht-Lundborg/diagnóstico , Síndrome de Unverricht-Lundborg/genética , Adulto , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/uso terapêutico , Southern Blotting , Feminino , Predisposição Genética para Doença , Humanos , Isoxazóis/administração & dosagem , Isoxazóis/uso terapêutico , Levetiracetam , Piracetam/administração & dosagem , Piracetam/análogos & derivados , Piracetam/uso terapêutico , República da Coreia , Resultado do Tratamento , Síndrome de Unverricht-Lundborg/tratamento farmacológico , Ácido Valproico/administração & dosagem , Ácido Valproico/uso terapêutico , ZonisamidaRESUMO
ABSTRACT The purpose of this study was to determine the effect of lamotrigine (LTG) and levetiracetam (LEV) as mono- and polytherapy on biochemical markers of bone turnover and bone mineral density in Egyptian adult patients with epilepsy. Methods Forty-eight patients were divided into four groups: two received monotherapy of either LTG or LEV, and the other two groups received polytherapy comprising (valproate [VPA] + LTG or VPA + LEV). Thirty matched healthy participants were included in the study. Participants completed a nutritional and physical activity questionnaire. Biochemical markers of bone and mineral metabolism and bone mineral density of the lumbar spine were measured at baseline and at six months. Results In the LEV monotherapy group, the bone formation markers showed a significant decrease in serum alkaline phosphatase and serum osteocalcin levels while the bone resorption marker showed a significant increase in urinary deoxypyridinoline levels. After six months of treatment, bone mineral density showed a significant decrease in all treated groups, while among monotherapy groups, this significant decrease was more prevalent in the LEV monotherapy group compared with the LTG monotherapy group. Furthermore, there was significant negative correlation between urinary deoxypyridinoline levels and bone mineral density in the LEV monotherapy group. Conclusion Using new generation antiepileptics, LEV monotherapies and polytherapy showed harmful effects on bone but LTG did not.
RESUMO O objetivo deste estudo foi determinar o efeito da lamotrigina (LTG) e levetiracetam (LEV) como mono e politerapia em marcadores bioquímicos de remodelação óssea e densidade mineral óssea em pacientes adultos egípcios com epilepsia. Métodos Quarenta e oito pacientes foram divididos em quatro grupos: dois grupos receberam monoterapia de LTG ou LEV e os outros dois grupos receberam politerapia (valproato [VPA] + LTG ou VPA + LEV). Trinta participantes saudáveis controle foram incluídos no estudo. Os participantes preencheram um questionário nutricional e de atividade física. Marcadores bioquímicos do metabolismo ósseo e mineral e densidade mineral óssea da coluna lombar foram medidos no início e aos seis meses. Resultados No grupo de monoterapia LEV, os marcadores de formação óssea mostraram uma diminuição significativa nos níveis séricos de fosfatase alcalina e osteocalcina sérica, enquanto o marcador de reabsorção óssea mostrou um aumento significativo nos níveis de desoxipiridinolina urinária. Após seis meses de tratamento, a densidade mineral óssea mostrou uma diminuição significativa em todos os grupos tratados, enquanto entre os grupos de monoterapia, esta diminuição significativa foi mais prevalente no grupo de monoterapia LEV em comparação com o grupo de monoterapia LTG. Além disso, houve correlação negativa significativa entre os níveis de desoxipiridinolina urinária e densidade mineral óssea no grupo de monoterapia LEV. Conclusão Utilizando antiepilépticos de nova geração, as monoterapias LEV e a politerapia mostraram efeitos prejudiciais no osso, mas a LTG não.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Adulto Jovem , Piracetam/análogos & derivados , Triazinas/efeitos adversos , Densidade Óssea/efeitos dos fármacos , Ácido Valproico/efeitos adversos , Remodelação Óssea/efeitos dos fármacos , Anticonvulsivantes/efeitos adversos , Piracetam/administração & dosagem , Piracetam/efeitos adversos , Triazinas/administração & dosagem , Biomarcadores/urina , Biomarcadores/sangue , Estudos de Casos e Controles , Osteocalcina/sangue , Ácido Valproico/administração & dosagem , Quimioterapia Combinada , Epilepsia/tratamento farmacológico , Lamotrigina , Levetiracetam , Aminoácidos/urina , Anticonvulsivantes/administração & dosagemRESUMO
Long-term anti-epileptic drug (AED) therapy compromises bone health. Although vitamin D deficiency is proposed to be involved, it alone is not held responsible. This accounts for investigating other mechanisms in bone accrual. Recent studies have shown modulation of inhibitors of wnt pathway, sclerostin and dickkopf-1 (DKK-1), in glucocorticoids-induced osteoporosis. We investigated whether AED monotherapy modulates wnt inhibitors in Indian women with epilepsy. Women of age > 20-40 years with the diagnosis of epilepsy and receiving AEDs (carbamazepine, valproate and levetiracetam) for at least a year were enrolled. The results were compared with age-matched healthy controls with no evidence of metabolic bone disease. Women undergoing treatment with AEDs (mean duration: 50.59 ± 37.929 months) exhibited higher serum sclerostin and receptor activator of nuclear factor κ B ligand (RANKL) and lower vitamin D (25-hydroxy vitamin D) and DKK-1 levels when compared to age-matched healthy controls. Sclerostin showed a positive correlation with RANKL, while DKK-1 presented no such relationship. However, no association was evident after adjusting for age, duration of treatment and total daily dose. Although a correlation between wnt inhibitors and RANKL could not be obtained, AEDs displayed changes in serum levels of wnt inhibitors in persons with epilepsy and hence these drugs may compromise bone health through a disturbance in wnt signalling mechanisms.
Assuntos
Anticonvulsivantes/efeitos adversos , Carbamazepina/efeitos adversos , Piracetam/análogos & derivados , Ácido Valproico/efeitos adversos , Proteínas Adaptadoras de Transdução de Sinal , Adulto , Anticonvulsivantes/administração & dosagem , Proteínas Morfogenéticas Ósseas/sangue , Carbamazepina/administração & dosagem , Estudos de Casos e Controles , Estudos Transversais , Epilepsia/tratamento farmacológico , Feminino , Marcadores Genéticos , Humanos , Índia , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Levetiracetam , Piracetam/administração & dosagem , Piracetam/efeitos adversos , Ligante RANK/sangue , Ácido Valproico/administração & dosagem , Vitamina D/análogos & derivados , Vitamina D/sangue , Via de Sinalização Wnt/efeitos dos fármacos , Adulto JovemRESUMO
OBJECTIVE: This study was conducted to develop a population pharmacokinetic (PK) model of levetiracetam in Korean neonates with seizures. MATERIALS AND METHODS: Data were obtained from a retrospective study of 18 neonates with seizures admitted to the Neonatal Intensive Care Unit (NICU) of Severance Children's Hospital for the period of from 2013 to 2015. Sampling and dosing times were recorded by clinical research coordinators on case report forms. Demographic factors and laboratory results were tested as potential covariates for PK parameters. Model development was performed within a mixed-effect modeling framework using NONMEM. RESULTS: With a one-compartment model with first-order elimination chosen as a basic PK model based on theory-based allometric relationships, postmenstrual age and serum creatinine were found to have significant influences on clearance (CL). Typical parameter estimates of the final PK model obtained, evaluated at covariate medians, were 1.08 L/kg for volume of distribution (V) and 0.073 L/h/kg (= 1.23 mL/min/kg) for CL, illustrating that V in Korean neonates is a little larger than in Western population while CL is similar. CONCLUSION: A population PK model of levetiracetam for Korean neonates with seizures was developed in this study. The result of this study can be used as a basis to develop an optimal dosage regimen in Korean neonates with seizures.â©.
Assuntos
Anticonvulsivantes/farmacocinética , Modelos Biológicos , Piracetam/análogos & derivados , Convulsões/tratamento farmacológico , Fatores Etários , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/sangue , Cálculos da Dosagem de Medicamento , Monitoramento de Medicamentos , Feminino , Hospitais Pediátricos , Humanos , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Levetiracetam , Masculino , Taxa de Depuração Metabólica , Piracetam/administração & dosagem , Piracetam/efeitos adversos , Piracetam/sangue , Piracetam/farmacocinética , República da Coreia , Estudos Retrospectivos , Convulsões/sangue , Convulsões/diagnósticoRESUMO
OBJECTIVE: We previously demonstrated that positive allosteric modulators (PAMs) of metabotropic glutamate subtype 2 (mGlu2 ) receptors have potential synergistic interactions with the antiseizure drug levetiracetam (LEV). The present study utilizes isobolographic analysis to evaluate the combined administration of JNJ-46356479, a selective and potent mGlu2 PAM, with LEV as well as sodium valproate (VPA) and lamotrigine (LTG). METHODS: The anticonvulsant efficacy of JNJ-46356479 was evaluated in the 6-Hz model of psychomotor seizures in mice. JNJ-46356479 was administered in combination with LEV using 3 fixed dose-ratio treatment groups in the mouse 6-Hz (44-mA) seizure test. The combination of JNJ-46356479 with LEV was also evaluated in the mouse corneal kindling model. The potential interactions of JNJ-46356479 with the antiseizure drugs VPA and LTG were also evaluated using fixed dose-ratio combinations. Plasma levels were obtained for analysis of potential pharmacokinetic interactions for each combination studied in the mouse 6-Hz model. RESULTS: JNJ-46356479 was active in the 6-Hz model at both 32-mA and 44-mA stimulus intensities (median effective dose = 2.8 and 10.2 mg/kg, respectively). Using 1:1, 1:3, and 3:1 fixed dose-ratio combinations (LEV:JNJ-46356479), coadministration was significantly more potent than predicted for additive effects, and plasma levels suggest this synergism was not due to pharmacokinetic interactions. Studies in kindled mice further demonstrate the positive pharmacodynamic interaction of LEV with JNJ-46356479. Using 1:1 dose-ratio combinations of JNJ-46356479 with either VPA or LTG, there were no significant differences observed for coadministration. SIGNIFICANCE: These studies demonstrate a synergistic interaction of JNJ-46356479 with LEV, whereas no such effect occurred for JNJ-46356479 with either VPA or LTG. The synergy seems therefore to be specific to LEV, and the combination LEV/mGlu2 PAM has the potential to result in a rational polypharmacy approach to treat patients with refractory epilepsy, once it has been confirmed in clinical studies.
Assuntos
Anticonvulsivantes/administração & dosagem , Agonistas de Aminoácidos Excitatórios/administração & dosagem , Piracetam/análogos & derivados , Receptores de Glutamato Metabotrópico/agonistas , Convulsões/tratamento farmacológico , Regulação Alostérica , Animais , Anticonvulsivantes/sangue , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Agonistas de Aminoácidos Excitatórios/sangue , Levetiracetam , Masculino , Camundongos , Piracetam/administração & dosagem , Piracetam/sangue , Receptores de Glutamato Metabotrópico/fisiologia , Convulsões/sangueRESUMO
Nine horses received 20 mg/kg of intravenous (LEVIV ); 30 mg/kg of intragastric, crushed immediate release (LEVCIR ); and 30 mg/kg of intragastric, crushed extended release (LEVCER ) levetiracetam, in a three-way randomized crossover design. Crushed tablets were dissolved in water and administered by nasogastric tube. Serum samples were collected over 48 hr, and levetiracetam concentrations were determined by immunoassay. Mean ± SD peak concentrations for LEVCIR and LEVCER were 50.72 ± 10.60 and 53.58 ± 15.94 µg/ml, respectively. The y-intercept for IV administration was 64.54 ± 24.99 µg/ml. The terminal half-life was 6.38 ± 1.97, 7.07 ± 1.93 and 6.22 ± 1.35 hr for LEVCIR , LEVCER, and LEVIV , respectively. Volume of distribution at steady-state was 630 ± 73.4 ml/kg. Total body clearance after IV administration was 74.40 ± 19.20 ml kg-1 hr-1 . Bioavailability was 96 ± 10, and 98 ± 13% for LEVCIR and LEVCER , respectively. A single dose of Levetiracetam (LEV) was well tolerated. Based on this study, a recommended dosing regimen of intravenous or oral LEV of 32 mg/kg every 12 hr is likely to achieve and maintain plasma concentrations within the therapeutic range suggested for humans, with optimal kinetics throughout the dosing interval in healthy adult horses. Repeated dosing and pharmacodynamic studies are warranted.
Assuntos
Anticonvulsivantes/farmacocinética , Piracetam/análogos & derivados , Animais , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/sangue , Estudos Cross-Over , Preparações de Ação Retardada , Feminino , Cavalos , Injeções Intravenosas/veterinária , Intubação Gastrointestinal/veterinária , Levetiracetam , Masculino , Piracetam/administração & dosagem , Piracetam/sangue , Piracetam/farmacocinéticaRESUMO
An 82-year-old man was admitted to the emergency department following bizarre behaviour. Police had noticed him driving erratically through his village. He did not stop when instructed, drove slowly home and appeared 'vacant' on questioning. While in hospital, he had approximately 15 episodes of catatonia, involving rigidity, negativism, mutism except echolalia and perseveration, automatic obedience and utilisation phenomena, lasting 2-20 min each. Between episodes, he was amnestic but otherwise well. Electroencephalography demonstrated bifrontal slowing with left-sided emphasis, and captured two focal onset partial seizures with the clinical correlate of the syndrome described above. He improved rapidly on levetiracetam and lorazepam, was discharged and received a diagnosis of dementia by his community mental health team shortly afterwards, based on chronic short-term memory loss, functional decline and MRI changes. This case has implications for our understanding of the neural correlate of catatonia, specifically frontal lobe pathway dysfunction.
Assuntos
Automatismo/diagnóstico , Catatonia/diagnóstico , Demência , Epilepsia do Lobo Frontal/diagnóstico , Idoso de 80 Anos ou mais , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/uso terapêutico , Automatismo/complicações , Automatismo/diagnóstico por imagem , Automatismo/tratamento farmacológico , Catatonia/complicações , Catatonia/diagnóstico por imagem , Catatonia/tratamento farmacológico , Diagnóstico Diferencial , Eletroencefalografia , Epilepsia do Lobo Frontal/complicações , Epilepsia do Lobo Frontal/diagnóstico por imagem , Epilepsia do Lobo Frontal/tratamento farmacológico , Humanos , Levetiracetam , Lorazepam/administração & dosagem , Lorazepam/uso terapêutico , Imageamento por Ressonância Magnética , Masculino , Piracetam/administração & dosagem , Piracetam/análogos & derivados , Piracetam/uso terapêuticoRESUMO
BACKGROUND: Treatment options for recurrent glioma of the brain include chemotherapy, radiotherapy, surgery, and palliation. Temozolomide appears to be effective in patients with recurrent high-grade gliomas. CASE DESCRIPTION: A middle-aged woman presented with a high-grade glioma of corpus callosum. The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered. The patient presented with significant recurrence 5 years later. Repeat surgery and radiation were suggested but refused. She was given temozolomide and dexamethasone intermittently, and levetiracetam was continued. Magnetic resonance imaging performed at 10-month follow-up showed 90% remission. CONCLUSIONS: There are a few reports in the literature of similar response to temozolomide and levetiracetam. Similar reports give more hope in the treatment of recurrent high grade glioma.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/terapia , Corpo Caloso , Recidiva Local de Neoplasia/tratamento farmacológico , Oligodendroglioma/terapia , Adulto , Neoplasias Encefálicas/diagnóstico por imagem , Quimiorradioterapia , Craniotomia , Dacarbazina/administração & dosagem , Dacarbazina/análogos & derivados , Descompressão Cirúrgica , Dexametasona/administração & dosagem , Feminino , Humanos , Levetiracetam , Imageamento por Ressonância Magnética , Recidiva Local de Neoplasia/diagnóstico por imagem , Oligodendroglioma/diagnóstico por imagem , Piracetam/administração & dosagem , Piracetam/análogos & derivados , Indução de Remissão , Temozolomida , Tomografia Computadorizada por Raios XRESUMO
OBJECTIVE: Brain tumor-related epilepsy (BTRE) is often drug resistant and patients can be forced to take polytherapy that can adversely affect their quality of life (QoL). Lacosamide (LCM) is a new antiepileptic drug (AED) used as adjunctive therapy in patients with partial seizures with or without secondary generalization, with a favorable pharmacokinetic profile that seems to be effective and well tolerated. Therefore it represents a possible therapeutic choice for patients with BTRE. We propose a prospective study with a historical control group to evaluate the effect of LCM as add-on therapy on seizure control and quality of life in patients with BTRE. This study has been designed to test the superiority of Lacosamide over Levetiracetam as an add-on. We compared a prospective cohort of 25 patients treated with Lacosamide with a historical control group (n=19) treated with Levetiracetam as an add-on. METHODS: We recruited 25 adult patients (M 18, F 7; mean age 41.9) affected by BTRE with uncontrolled partial-onset seizures treated with AED polytherapy. We added LCM as an add-on. Patients were evaluated at baseline, after 3months and at 6months. This population has been compared with a historical control group of 19 BTRE adult patients (M 13, F 6; median age 48.0, range: 28-70) with uncontrolled partial-onset seizures treated with LEV as add-on. The patients underwent QoL, mood and adverse events tests (Adverse Event Profile-AEP) and evaluation of seizure frequency. RESULTS: Twelve patients had high grade gliomas, and thirteen had low grade gliomas. During follow-up, thirteen patients underwent chemotherapy, three radiotherapy and five patients had disease progression. Nine patients had simple partial seizures, eight had complex partial seizures, and eight had secondary generalized seizures. Fifteen patients were in monotherapy and ten in polytherapy with AEDs. LCM was added up to reach the maximum dosage of 400mg/die (mean final dose 300mg/die). Four patients dropped out due to poor compliance and 1 for inefficacy. In the historical control group treated with LEV (mean final dose 2000mg/die) 12 patients had high-grade gliomas, and 7 had low grade gliomas. Thirteen patients were in monotherapy and 6 in polytherapy with AEDs. In the 22 patients evaluable of 25 patients treated with LCM, we observed at final follow-up 7 patients seizure free, 12 with a significant reduction of seizures≥50%, 2 stable and 1 patient with number of seizures increased. Mean seizure frequency at baseline compared with baseline period: the mean number of seizures significantly decreased from baseline (9.4) to final follow-up (1.2) (P=0.005). The Responder Rate was 86.4%. Comparing responder rate of 22 evaluable patients with LCM with responder rate of 19 patients with LEV we didn't observe significant differences (p=0.31). In our patients treated with LCM we didn't observe significant difference at 3 and 6months in QoL tests results; we observe a significant reduction in the mean score of Karnofsky Performance Status (KPS) and Barthel Index (BI) between baseline and 6months of follow-up (KPS p=0.003; BI p=0.007). No clinical side effects were observed. CONCLUSION: Comparing the LCM with the historical group treated with LEV in add-on, we observed that LCM seems to have a higher clinical efficacy than LEV. In our patients, we did not observe any significant changes in QoL tests, indicating stability in all quality of life domains explored, despite the objective worsening in their functional status. Although this is a small series with a relatively short follow-up, our data indicates that LCM in add-on in patients with BTRE appears to be as effective as LEV in add-on, without impact on mood and quality of life.
Assuntos
Acetamidas/farmacologia , Afeto/efeitos dos fármacos , Anticonvulsivantes/farmacologia , Neoplasias Encefálicas/complicações , Epilepsia/tratamento farmacológico , Epilepsia/etiologia , Estudo Historicamente Controlado/métodos , Avaliação de Resultados em Cuidados de Saúde , Piracetam/análogos & derivados , Qualidade de Vida , Acetamidas/administração & dosagem , Adulto , Idoso , Anticonvulsivantes/administração & dosagem , Quimioterapia Combinada , Epilepsias Parciais/tratamento farmacológico , Feminino , Humanos , Lacosamida , Levetiracetam , Masculino , Pessoa de Meia-Idade , Piracetam/administração & dosagem , Piracetam/farmacologia , Estudos ProspectivosRESUMO
A 55-year-old man with no mental retardation had presented a history of frequent transient clumsiness of his right upper and lower extremities for about 20 years. He was admitted to a general hospital with weakness of right side of the body, and first-ever generalized seizure attack occurred the next day. Brain CT showed calcification in the left cerebral cortices. So he was referred to our hospital. On neurological examination, he had mild clumsiness of his right upper limb and right pyramidal tract sign. He had neither facial port-wine stain nor glaucoma. The blood test and cerebrospinal fluid analysis were unremarkable. Electroencephalogram showed slowing and reduction of activity at the left frontal and parietal areas with no epileptic activities. Brain CT showed "tram-track calcification" and lobar atrophy in the left fronto-parietal cortices. Susceptibility weighted imaging (SWI) on MRI revealed enlarged transmedullary veins in the left periventricular white matter and low intensity lesions along the cortical gyri. Post gadolinium fluid-attenuated inversion recovery imaging (FLAIR-Gd) showed leptomeningeal enhancement in the left fronto-parietal lobes more extensively than those by post gadolinium T1-weighted image. Brain perfusion single photon emission computed tomography with a technetium-99m-ethyl cysteinate dimer (99mTc-ECD SPECT) revealed hypoperfusion in the fronto-parietal lobes. These clinical and neuroimaging findings were compatible with type III Sturge-Weber syndrome (SWS). His condition was improved after treatment with oral levetiracetam (1,000â mg daily). Although adult-onset type III SWS is very rare, it is important to perform SWI and post-contrast FLAIR for assessing leptomeningeal angioma in patients with seizure with focal cortical calcification even if they have no facial nevus.
Assuntos
Encéfalo/diagnóstico por imagem , Imageamento por Ressonância Magnética , Convulsões/etiologia , Síndrome de Sturge-Weber/complicações , Síndrome de Sturge-Weber/diagnóstico por imagem , Administração Oral , Humanos , Transtornos de Início Tardio , Levetiracetam , Masculino , Pessoa de Meia-Idade , Piracetam/administração & dosagem , Piracetam/análogos & derivados , Síndrome de Sturge-Weber/classificação , Síndrome de Sturge-Weber/tratamento farmacológico , Tomografia Computadorizada de Emissão de Fóton Único , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND: Pyrexia is a physiological response through which the immune system responds to infectious processes. Hyperpyrexia is known to be neurodegenerative leading to brain damage. Some of the neurotoxic effects of hyperpyrexia on the brain include seizures, decreased cognitive speed, mental status changes, coma, and even death. In the clinical management of hyperpyrexia, the goal is to treat the underlying cause of elevated temperature and prevent end organ damage. CASE PRESENTATION: This case illustrates a 39-year-old white American man referred from another medical facility where he had undergone an upper gastrointestinal tract diagnostic procedure which became complicated by blood aspiration and respiratory distress. During hospitalization, he developed a core body temperature of 41.6 °C (106.9 °F) leading to cognitive decline and coma with a Glasgow Coma Score of 3. Levetiracetam and amantadine were utilized effectively for preserving and restoring neurocognitive function. Prior studies have shown that glutamate levels can increase during an infectious process. Glutamate is an excitatory neurotransmitter that is utilized by the organum vasculosum laminae terminalis through the neuronal excitatory system and causes an increase in body temperature which can lead to hyperpyrexia. Similar to neurogenic fevers, hyperpyrexia can lead to neurological decline and irreversible cognitive dysfunction. Inhibition of the glutamate aids a decrease in excitatory states, and improves the brain's regulatory mechanism, including temperature control. To further improve cognitive function, dopamine levels were increased with a dopamine agonist. CONCLUSIONS: We propose that a combination of levetiracetam and amantadine may provide neuroprotective and neurorestorative properties when administered during a period of hyperpyrexia accompanied by any form of mental status changes, particularly if there is a decline in Glasgow Coma Score.
Assuntos
Amantadina/administração & dosagem , Anticonvulsivantes/administração & dosagem , Transtornos Cognitivos/tratamento farmacológico , Dopaminérgicos/administração & dosagem , Hipertermia Maligna/tratamento farmacológico , Piracetam/análogos & derivados , Adulto , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Lesões Encefálicas/complicações , Lesões Encefálicas/tratamento farmacológico , Transtornos Cognitivos/complicações , Coma/complicações , Quimioterapia Combinada , Ácido Glutâmico/metabolismo , Humanos , Levetiracetam , Masculino , Hipertermia Maligna/complicações , Piracetam/administração & dosagem , Tomografia Computadorizada por Raios XRESUMO
Objectives Currently, there are no published randomised, controlled veterinary trials evaluating the efficacy of antiepileptic medication in the treatment of myoclonic seizures. Myoclonic seizures are a hallmark of feline audiogenic seizures (FARS). Methods This prospective, randomised, open-label trial compared the efficacy and tolerability of levetiracetam (20-25 mg/kg q8h) with phenobarbital (3-5 mg/kg q12h) in cats with suspected FARS that experienced myoclonic seizures. Cats were included that had ⩾12 myoclonic seizure days during a prospective 12 week baseline period. This was followed by a 4 week titration phase (until a therapeutic serum concentration of phenobarbital was achieved) and a 12 week treatment phase. Results Fifty-seven cats completed the study: 28 in the levetiracetam group and 29 in the phenobarbital group. A reduction of ⩾50% in the number of myoclonic seizure days was seen in 100% of patients in the levetiracetam group and in 3% of patients in the phenobarbital group ( P <0.001) during the treatment period. Levetiracetam-treated cats had higher freedom from myoclonic seizures (50.0% vs 0%; P <0.001) during the treatment period. The most common adverse events were lethargy, inappetence and ataxia, with no difference in incidence between levetiracetam and phenobarbital. Adverse events were mild and transient with levetiracetam but persistent with phenobarbital. Conclusions and relevance These results suggest that levetiracetam is an effective and well tolerated treatment for cats with myoclonic seizures and is more effective than phenobarbital. Whether it will prevent the occurrence of generalised tonic-clonic seizures and other forebrain signs if used early in the course of FARS is not yet clear.
Assuntos
Anticonvulsivantes/administração & dosagem , Doenças do Gato/tratamento farmacológico , Epilepsia Generalizada/veterinária , Piracetam/análogos & derivados , Convulsões/veterinária , Animais , Gatos , Epilepsias Mioclônicas , Epilepsia Generalizada/tratamento farmacológico , Feminino , Humanos , Levetiracetam , Masculino , Piracetam/administração & dosagem , Estudos Prospectivos , Convulsões/tratamento farmacológicoRESUMO
Neurocysticercosis is the common parasitic disease of the central nervous system. One of the uncommon manifestations and a rare complication is its disseminated form. Human cysticercosis is caused by the spreading of the embryo of Taenia solium in the intestine via the hepatoportal system to different tissues and internal organs of the body. The organs most commonly affected are the subcutaneous tissue, skeletal muscles, lungs, brain, eyes, liver, and occasionally the heart, thyroid, and pancreas. We report a case of a 62 year old male, who has been presented, with seizures and subcutaneous nodules on both extremities. After investigation he was diagnosed as a case of disseminated cysticercosis involving brain, subcutaneous tissue, liver, muscles and pericardial fat.
Assuntos
Cisticercose/patologia , Albendazol/administração & dosagem , Albendazol/uso terapêutico , Anti-Helmínticos/administração & dosagem , Anti-Helmínticos/uso terapêutico , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/uso terapêutico , Cisticercose/diagnóstico , Cisticercose/tratamento farmacológico , Humanos , Levetiracetam , Masculino , Pessoa de Meia-Idade , Fenitoína/administração & dosagem , Fenitoína/uso terapêutico , Piracetam/administração & dosagem , Piracetam/análogos & derivados , Piracetam/uso terapêutico , Praziquantel/administração & dosagem , Praziquantel/uso terapêutico , Prednisolona/administração & dosagem , Prednisolona/uso terapêutico , Convulsões/tratamento farmacológicoRESUMO
Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12â months, increased to 14.6â months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Glioblastoma/tratamento farmacológico , Segunda Neoplasia Primária/tratamento farmacológico , Astrocitoma/radioterapia , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/radioterapia , Transtornos Cognitivos/tratamento farmacológico , Dacarbazina/administração & dosagem , Dacarbazina/análogos & derivados , Dexametasona/administração & dosagem , Glioblastoma/diagnóstico , Humanos , Levetiracetam , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Regressão Neoplásica Espontânea , Segunda Neoplasia Primária/diagnóstico , Piracetam/administração & dosagem , Piracetam/análogos & derivados , TemozolomidaRESUMO
BACKGROUND & OBJECTIVES: Though newer antiepileptic drugs are considered safer than conventional antiepileptics, the effects of lamotrigine, levetiracetam and topiramate on neurobehavioural functions are yet to be established. This study evaluated neurobehavioural parameters and oxidative stress markers in brain tissue of rats treated with lamotrigine, levetiracetam and topiramate compared to sodium valproate . METHODS: Five groups of male Wistar rats were treated respectively with normal saline (control), sodium valproate (370 mg/kg), lamotrigine (50 mg/kg), levetiracetam (310 mg/kg) and topiramate (100 mg/kg) for 45 days. Neurobehavioural parameters were assessed using elevated plus maze (EPM), actophotometer, rotarod, passive avoidance and Morris water maze (MWM) at baseline and at the end of treatment. Oxidative stress parameters [malondialdehyde (MDA), reduced glutathione (GSH) and superoxide dismutase (SOD)] were estimated in rat brain at the end of treatment. RESULTS: Valproate and lamotrigine showed no significant effect on learning and memory in passive avoidance and MWM tests. However, levetiracetam and topiramate reduced retention memory significantly as compared to control (P<0.01) and lamotrigine (P<0.05) groups. Performances on EPM, rotarod and actophotometer were not significantly different between the groups. In comparison to control group, MDA was higher in the levetiracetam and topiramate (360.9 and 345.9 nmol/g of homogenized brain tissue, respectively) groups. GSH and SOD activity were significantly reduced by valproate and levetiracetam treatment. Lamotrigine did not induce significant oxidative stress. INTERPRETATION & CONCLUSIONS: Long-term and therapeutic dose treatment with levetiracetam and topiramate significantly impaired learning and memory, which was not seen with valproate and lamotrigine in rats. Levetiracetam, topiramate and valproate augmented oxidative stress, whereas lamotrigine has little effect on it. These antiepileptic drugs are used in clinical practice, hence pharmaco- vigilance studies are required to evaluate their safety profile.
Assuntos
Encéfalo/efeitos dos fármacos , Aprendizagem/efeitos dos fármacos , Memória/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Animais , Encéfalo/metabolismo , Encéfalo/fisiologia , Frutose/administração & dosagem , Frutose/análogos & derivados , Glutationa/metabolismo , Lamotrigina , Aprendizagem/fisiologia , Levetiracetam , Masculino , Malondialdeído/metabolismo , Memória/fisiologia , Piracetam/administração & dosagem , Piracetam/análogos & derivados , Ratos , Superóxido Dismutase/metabolismo , Topiramato , Triazinas/administração & dosagem , Ácido Valproico/administração & dosagemRESUMO
BACKGROUND: Delayed elimination of methotrexate was previously reported in 2 patients receiving concomitant levetiracetam. OBJECTIVE: To explore the potential interaction between methotrexate and levetiracetam in patients receiving high-dose methotrexate. METHODS: This retrospective study reviewed the records of 81 adults receiving 280 cycles of methotrexate to determine the effects of levetiracetam on methotrexate elimination. Institutional review board approval was obtained. RESULTS: Levetiracetam was administered in 33 (12%) cycles of methotrexate. Patients receiving levetiracetam had significantly lower 24-hour methotrexate concentrations compared with those not receiving levetiracetam (2.91 vs 7.37 µmol/L, P = 0.005). Despite this difference, concentrations at 48 and 72 hours were similar between groups. Times to nontoxic methotrexate concentration (<0.1 µmol/L) were the same regardless of the presence of levetiracetam. The frequency of delayed elimination at 24, 48, and 72 hours was similar in both groups as was the frequency of delayed elimination at any time point. Cox regression demonstrated that levetiracetam was not a significant predictor of time to nontoxic methotrexate concentration (P = 0.796; HR = 1.058; 95% CI = 0.692-1.617), and logistic regression demonstrated that levetiracetam was not a significant predictor of delayed elimination at any time point. Levetiracetam use was similar between groups when comparing patients experiencing delayed elimination at any time point with those without delayed elimination (13% vs 10%, respectively, P = 0.527). CONCLUSION: This study does not support the previous reports of a significant interaction between levetiracetam and methotrexate. A clinically significant interaction is unlikely in those without additional risk factors for delayed elimination.
Assuntos
Anticonvulsivantes/administração & dosagem , Antimetabólitos Antineoplásicos/farmacocinética , Metotrexato/farmacocinética , Piracetam/análogos & derivados , Adulto , Anticonvulsivantes/uso terapêutico , Antimetabólitos Antineoplásicos/administração & dosagem , Antimetabólitos Antineoplásicos/sangue , Antimetabólitos Antineoplásicos/uso terapêutico , Interações Medicamentosas , Feminino , Humanos , Levetiracetam , Modelos Logísticos , Masculino , Taxa de Depuração Metabólica , Metotrexato/administração & dosagem , Metotrexato/sangue , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Piracetam/administração & dosagem , Piracetam/uso terapêutico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de RiscoRESUMO
Experiments on small (rats) and large (dogs) animals have shown that a sequential administration of Palonosetron and Phenotropil decreases the intensity of the main manifestations of the N-V-D stage of acute radiation syndrome. These data show the appropriateness of a combined administration of Palonosetron and Phenotropil to prevent a reduced work capacity in the individuals participating in elimination of the consequences of accidents associated with overexposure to radiation.